Hormonal and metabolic features of the androgenic phenotypes of polycystic ovary syndrome and non-classic adrenal hyperplasia with various polymorphic variants in the CYP17A1 gene

Cover Page


Cite item

Full Text

Abstract

The CYP17A1 gene encodes the most important stages of sex steroid biosynthesis by the adrenal glands and ovaries. The objective of this study was to evaluate the hormonal and metabolic status of patients with hyperandrogenia and the CYP17A1 rs743572 gene polymorphism. We examined 106 women with polycystic ovary syndrome androgen phenotypes A, B, and C and 28 women with latent non-classic congenital adrenal hyperplasia. It was found that there were no significant differences in the frequency of CYP17A1 alleles and genotypes between the three phenotype groups of patients with polycystic ovary syndrome. Body mass index and insulin resistance after glucose loading were comparable in individuals with these phenotypes of polycystic ovary syndrome. The CYP17A1 gene polymorphism in patients with different polycystic ovary syndrome phenotypes and in individuals with latent non-classic congenital adrenal hyperplasia did not associate with the concentration of estradiol and androgens in the blood. Neither did LH / FSH ratio differ between groups with different allelic variants of the CYP17A1 gene. These results show that patients with different polycystic ovary syndrome phenotypes do not require differentiated therapy. Serum levels of DHEA-S and cortisol were elevated in 38.7% of women with polycystic ovary syndrome without non-classic congenital adrenal hyperplasia, which indicates an adrenal cause of hyperandrogenia. We suppose that in the diagnosis of polycystic ovary syndrome, it is necessary to define not only phenotypes, but also a suprarenal source of androgens. The therapy of these patients may require application of corticosteroids besides the usual methods in planning of pregnancy.

About the authors

Evgeny K. Komarov

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Author for correspondence.
Email: evg_komarov@mail.ru

MD, PhD, DSci (Medicine), Leading Researcher. The Obstetric Department of Pregnancy Pathology I

Russian Federation, Saint Petersburg

Elena A. Mikhnina

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott; Academician I.P. Pavlov First St. Petersburg State Medical University

Email: emikhnina@yandex.ru
SPIN-code: 3190-2307

MD, PhD, DSci (Medicine), Professor. The Consultative and Diagnostic Department; the Department of Obstetrics, Gynecology, and Reproductive Sciences

Russian Federation, Saint Petersburg

Natalia S. Osinovskaya

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: natosinovskaya@mail.ru
ORCID iD: 0000-0001-7831-9327
SPIN-code: 3190-2307

PhD, Senior Researcher. The Laboratory for Prenatal Diagnosis of Congenital and Hereditary Diseases

Russian Federation, Saint Petersburg

References

  1. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1-13. https://doi.org/10.2147/CLEP.S37559.
  2. Joseph S, Barai RS, Bhujbalrao R, Idicula-Thomas S. PCOSKB: a knowledge base on genes, diseases, ontology terms and biochemical pathways associated with polycystic ovary syndrome. Nucleic Acids Res. 2016;44(D1):D1032-1035. https://doi.org/10.1093/nar/gkv1146.
  3. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 2004;25(6):947-970. https://doi.org/10.1210/er.2003-0030.
  4. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994;3(10):1873-1876. https://doi.org/10.1093/hmg/3.10.1873.
  5. Nedelcheva KV, Haraldsen EK, Anderson KB, et al. CYP17 and breast cancer risk: the polymorphism in the 5’ flanking area of the gene does not influence binding to Sp-1. Cancer Res. 1999;59(12):2825-2828.
  6. Haiman CA, Hankinson SE, Spiegelman D, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res. 1999;59(5):1015-1020.
  7. Small CM, Marcus M, Sherman SL, et al. CYP17 genotype predicts serum hormone levels among pre-menopausal women. Hum Reprod. 2005;20(8):2162-2167. https://doi.org/10.1093/humrep/dei054.
  8. Feigelson HS, Coetzee GA, Kolonel LN, et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997;57(6):1063-1065.
  9. Bozdag G, Alp A, Saribas Z, et al. CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis. Reprod Biomed Online. 2010;20(2):286-290. https://doi.org/10.1016/j.rbmo.2009.11.007.
  10. Berstein LM, Imyanitov EN, Gamajunova VB, et al. CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? Cancer Lett. 2002;180(1):47-53. https://doi.org/10.1016/s0304-3835(02)00019-8.
  11. Travis RC, Churchman M, Edwards SA, et al. No association of polymorphisms in CYP17, CYP19, and HSD17-B1 with plasma estradiol concentrations in 1,090 British women. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2282-2284.
  12. Asghar T, Yoshida S, Nakago S, et al. Lack of association between endometriosis and the CYP17 MspA1 polymorphism in UK and Japanese populations. Gynecol Endocrinol. 2005;20(2):59-63. https://doi.org/10.1080/ 09513590400020856.
  13. Chen HY, Pang LH, Yang DM, et al. Association study between CYP17 gene polymorphism and endometriosis risk: a meta-analysis. J Obstet Gynaecol Res. 2015;41(4):497-504. https://doi.org/10.1111/jog.12622.
  14. Marszalek B, Laciński M, Babych N, et al. Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5’-UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2001;15(2):123-128. https://doi.org/10.1080/gye.15.2.123.128.
  15. Pusalkar M, Meherji P, Gokral J, et al. CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome. Fertil Steril. 2009;92(2):653-659. https://doi.org/10.1016/j.fertnstert. 2008.07.016.
  16. Echiburú B, Pérez-Bravo F, Maliqueo M, et al. Polymorphism T→C (-34 base pairs) of gene CYP17 promoter in women with polycystic ovary syndrome is associated with increased body weight and insulin resistance: a preliminary study. Metabolism. 2008;57(12):1765-1771. https://doi.org/10.1016/j.metabol.2008.08.002.
  17. Li L, Gu ZP, Bo QM, et al. Association of CYP17A1 gene -34T/C polymorphism with polycystic ovary syndrome in Han Chinese population. Gynecol Endocrinol. 2015;31(1):40-43. https://doi.org/10.3109/09513590.2014.947948.
  18. Беглова А.Ю., Елгина С.И., Артымук Н.В., Гордеева Л.А. Полиморфизм генов цитохромов у женщин с синдромом поликистозных яичников // Фундаментальная и клиническая медицина. – 2019. – Т. 4. – № 3. – С. 8−14. [Beglova AYu, Yelgina SI, Artymuk NV, Gordeeva LA. Polymorphisms of cytochrome genes in women with polycystic ovary syndrome. Fundamental and clinical medicine. 2019;4(3):8-14. (In Russ.)]. https://doi.org/10.23946/2500-0764-2019-4-3-8-14.
  19. Pérez MS, Cerrone GE, Benencia H, et al. [Polymorphism in CYP11alpha and CYP17 genes and the etiology of hyperandrogenism in patients with polycystic ovary syndrome. (In Spanish)]. Medicina (B Aires). 2008;68(2):129-134.
  20. Kaur R, Kaur T, Kaur A. Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome. J Assist Reprod Genet. 2018;35(6):1123-1129. https://doi.org/10.1007/s10815-018-1162-0.
  21. Li Y, Liu F, Luo S, et al. Polymorphism T→C of gene CYP17 promoter and polycystic ovary syndrome risk: a meta-analysis. Gene. 2012;495(1):16-22. https://doi.org/10.1016/ j.gene.2011.12.048.
  22. Banerjee U, Dasgupta A, Khan A, et al. A cross-sectional study to assess any possible linkage of C/T polymorphism in CYP17A1 gene with insulin resistance in non-obese women with polycystic ovarian syndrome. Indian J Med Res. 2016;143(6):739-747. https://doi.org/10.4103/0971-5916.191990.
  23. Zhang HY, Guo CX, Zhu FF, et al. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycysticovary syndrome: a large-scale case-control study. Arch Gynecol Obstet. 2013;287(3):525-531. https://doi.org/10.1007/s00404-012-2568-z.
  24. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. https://doi.org/10.1016/j.fertnstert.2003.10.004.
  25. Da Silva RC, Miranda WL, Chacra AR, Dib SA. Insulin resistance, beta-cell function, and glucose tolerance in Brazilian adolescents with obesity or risk factors for type 2 diabetes mellitus. J Diabetes Complications. 2007;21(2):84-92. https://doi.org/10.1016/j.jdiacomp.2005.11.006.
  26. Осиновская Н.С. Врожденная гиперплазия коры надпочечников (ВГКН) как дефицит 21-гидроксилазы: современное представление и генетическая диагностика // Молекулярно-биологические технологии в медицинской практике: сборник. – Вып. 9. – Новосибирск: Альфа-Виста, 2006. – С. 84−108. [Osinovskaya NS. Vrozhdennaya giperplaziya kory nadpochechnikov (VGKN) kak defitsit 21-gidroksilazy: sovremennoye predstavleniye i geneticheskaya diagnostika. In: Molekulyarno-biologicheskiye tekhnologii v meditsinskoy praktike: sbornik. Issue 9. Novosibirsk: Al’fa-Vista; 2006. Р. 84-108. (In Russ.)]
  27. Чернуха Г.Е., Блинова И.В., Купрашвили М.И. Эндокринно-метаболические характеристики больных с различными фенотипами синдрома поликистозных яичников // Акушерство и гинекология. − 2011. − № 2. − С. 70−76. [Chernukha GE, Blinova IV, Kuprashvili MI. Endocrine and metabolic characteristics of patients with different phenotypes of polycystic ovary syndrome. Akusherstvo i ginekologiia. 2011;(2):70-76. (In Russ.)]
  28. Гафарова Е.А. Клинико-лабораторные проявления СПКЯ в зависимости от фенотипических особенностей и уровня витамина D в крови // Практическая медицина. − 2016. − № 1. – С. 80−84. [Gafarova EA. Clinical and laboratory manifestations of PCOS depending on phenotypic characteristics and vitamin D blood level. Practical medicine. 2016;(1):80-84. (In Russ.)]
  29. Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2016;293(2):447-456. https://doi.org/10.1007/s00404-015-3889-5.
  30. Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. A case-control observation study of insulin resistence and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Reprod Health. 2015;12(7). https://doi.org/10.11867/1742-4755-12-7.
  31. Carmina E, Lobo RA. Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. J Endocrinol Invest. 2007;30(2):111-116. https://doi.org/10.1007/BF03347408.
  32. Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol. 2015;145:213-225. https://doi.org/10.1016/j.jsbmb.2014.06.003.

Copyright (c) 2020 Komarov E.K., Mikhnina E.A., Osinovskaya N.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies